ReproCELL
ReproCELL Incorporated is primarily engaged in the development of stem cell technologies.
Launch date
Employees
Market cap
€80.3m
Enterprise valuation
€39m (Public information from Sep 2024)
Share price
JPY129 4978.T
Yokohama Kanagawa Prefecture (HQ)
Financials
Estimates*
| JPY | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | 1.2b | 1.3b | 2.2b | 3.0b | 2.4b | 374m | 412m |
| % growth | - | 7 % | 74 % | 32 % | (18 %) | (85 %) | 10 % |
| EBITDA | (838m) | (766m) | (438m) | (116m) | 78.0m | (300m) | (140m) |
| % EBITDA margin | (70 %) | (60 %) | (20 %) | (4 %) | 3 % | (80 %) | (34 %) |
| Profit | (1.0b) | (813m) | (575m) | (305m) | (31.4m) | (170m) | (20.0m) |
| % profit margin | (85 %) | (63 %) | (26 %) | (10 %) | (1 %) | (45 %) | (5 %) |
| EV / revenue | 17.6x | 19.5x | 6.3x | 4.8x | 3.1x | 17.0x | 15.7x |
| EV / EBITDA | -25.2x | -32.7x | -31.9x | -121.8x | 95.5x | -21.2x | -46.1x |
| R&D budget | 455m | 662m | 535m | 502m | 385m | - | - |
| R&D % of revenue | 38 % | 51 % | 24 % | 17 % | 16 % | - | - |
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
N/A | Early VC | ||
$2.0m | Early VC | ||
| N/A | N/A | IPO | |
* | N/A | Grant | |
| Total Funding | €1.8m | ||
Related Content
Recent News about ReproCELL
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.
